The Indian Council of Medical Research on Monday said antiviral medication remdesivir, which was utilized during the Ebola episode, might be profoundly powerful in halting the replication component of <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technical-guidance/naming-the-coronavirus-disease-(covid-2019)-and-the-virus-that-causes-it">SARS-CoV-2 that causes COVID-19.</a></span>

The ICMR said investigate on its viability in the treatment of COVID-19 is a piece of <span style="color: #ff6600;"><a style="color: #ff6600;" href="https://www.who.int/">WHO's</a> </span>"Solidarity Trial".

As indicated by an as of late distributed investigation in the New England Journal of Medicine, two out of three basically sick coronavirus tainted patients who were on oxygen support or on ventilators gave indications of progress when they were regulated remdesivir.

<span style="text-decoration: underline;">Remarking on the investigation, Head of Epidemiology and Communicable infections at ICMR Raman R Gangakhedkar said that medicate which was utilized against Ebola infection, as indicated by the scientists, prevents the propagation of coronavirus which is the reason they accept that it could be powerful in COVID-19 treatment.</span>